Monitor for the company's 15-day response and any subsequent FDA communications. The warning letter creates regulatory overhang that could pressure the stock until resolution. Watch for potential production restrictions or additional enforcement actions if remediation is deemed inadequate.
Price Chart
Executive Summary
Amphastar subsidiary IMS received an FDA Warning Letter for CGMP violations at its South El Monte, CA manufacturing facility following a December 2025 inspection. The letter cites deficiencies in investigation procedures, environmental monitoring, and equipment handling, but does not order product cessation or recall. IMS continues operations and must submit a response and remediation plan within 15 working days. The regulatory overhang creates uncertainty around potential future FDA actions.
Key Facts
- Subsidiary IMS received FDA Warning Letter on July 2, 2026 for South El Monte facility
- CGMP violations cited: investigation procedures, environmental monitoring, handling procedures, manufacturing equipment
- FDA does not direct cessation or restriction of products, nor require further recall
- IMS must submit initial response within 15 working days, conduct risk assessment, and submit remediation plan
- Company is evaluating impact on business operations; additional regulatory action possible until deficiencies resolved
Financial Impact
No financial exposure quantified in filing; potential remediation costs and risk of future production disruption if FDA is not satisfied
Risk Factors
- FDA may impose additional restrictions or enforcement actions if response is unsatisfactory
- Remediation costs and potential production delays could impact financial performance
- Uncertainty around timing of resolution may weigh on near-term sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001297184-26-000041 |
| Document: 0001297184-26-000041-index-headers.html | 0001297184-26-000041 |
| Document: 0001297184-26-000041-index.html | 0001297184-26-000041 |
| Document: 0001297184-26-000041.txt | 0001297184-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | Insider Cluster | $26.27 | awaiting T+60 | — | $25.32 (−3.62%) |
Sep 21, 2026 4w ago | 144 | $24.32 | awaiting T+60 | — | $25.32 (+4.11%) |
Aug 21, 2026 9w ago | Institutional Cluster | $21.60 | awaiting T+60 | — | $25.32 (+17.22%) |
Aug 12, 2026 10w ago | Insider Cluster | $20.18 | awaiting T+60 | — | $25.32 (+25.47%) |
Aug 11, 2026 10w ago | 144 | $20.31 | awaiting T+60 | — | $25.32 (+24.67%) |
Jul 13, 2026 15w ago | 8-K | $19.29 $25.91 | ▲ +34.32% | ▲ +30.32% | $25.32 (+31.26%) |
Jul 7, 2026 15w ago | 8-K | $18.88 $25.35 | ▼ −34.27% | ▼ −31.78% | $25.32 (−34.11%) |
Apr 13, 2026 27w ago | DEFA14A | $21.38 $19.02 | ▼ −11.04% | ▼ −19.56% | $25.32 (+18.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers